On November 2, 2021 Applied DNA Sciences, Inc. a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies reported that signing a mutual collaboration agreement with India based Ganesha Ecosphere Ltd., the largest recycled polyester (rPET) fiber producer in India with over 300-plus customers, 250-plus suppliers, and 500-plus product variants (Press release, Applied DNA Sciences, NOV 2, 2021, View Source [SID1234594094]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the Agreement, Ganesha will deploy the CertainT platform, Applied DNA’s traceability system, to tag an initial pilot production of recycled polyester (rPET) at Ganesha’s facilities in India and conduct confirmatory samples testing at Applied DNA’s laboratories in India and the U.S.

The collaboration between the two companies will provide brands and textile manufacturers with a trusted solution to support their sustainability goals for rPET and confirm raw material authenticity at all stages of the textile value chain.

The Agreement enables Ganesha to introduce and apply CertainT-verified rPET to provide assurance for the raw material with textile and apparel customers. Ganesha will also employ Applied DNA’s recently introduced SigNature T-100 tracer system that enables rPET source material to be quantified in polyester blends by the CertainT platform.

SigNature T-100 is a proprietary molecular-based tracer system used to identify, analyze, and verify rPET, polypropylene, acrylic, and potentially other man-made materials for claims of both identification and quantification of the raw material tagged and subsequently spun into yarn for various textile products.

"Traceability has now added more authenticity and credibility to the entire textile supply chain and is becoming an integral part of the recycling process. With Applied DNA and CertainT, our customers can now trust in the original tagged synthetic fiber and verify product-related sustainability claims," stated Mr. B.P. Sultania, Joint President of Ganesha Ecosphere Ltd.

Since entering the rPET business in 1994, Ganesha has pioneered the manufacturing of rPET fiber and rPET yarn from post-consumer PET bottle scrap under the leadership and vision of Chairman Shyam Sunder Sharmma.

The company is the largest producer of rPET fiber, spun yarn, and dyed filament with a cumulative capacity of 118,800 metric tons per annum in India. Ganesha’s rPET products are components in the manufacture of textiles, such as T-shirts, body warmers and functional textiles such as nonwoven air filter fabric, geo textiles, carpets, and car upholstery, and fillings for pillows, duvets, and toys.

"CertainT provides garment brands and manufacturers with a real strategic advantage that is truly sustainable, traceable and trusted. Our India and Asia-based support teams for recycled PET and other polymers facilitate CertainT’s commercial scale-up and integration into customers’ supply chain," stated Dr. James A. Hayward, president, and CEO of Applied DNA Sciences.

On November 2, 2021 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-and small molecule-based targeted therapeutics, reported that it will announce its Third Quarter 2021 Results for the three months ended 30th September 2021 following a Board of Director’s meeting to be held on Thursday 11th November 2021 (Press release, Philogen, NOV 2, 2021, View Source [SID1234594092]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at 11 am EST / 4 pm GMT / 5 pm CEST on Friday 12th November 2021.

For more details or to attend the virtual briefing, please contact [email protected].

On November 2, 2021 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported that revenues from product sales of Monjuvi (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarter of 2021 and € 46.4 million (US$ 55.5 million) for the first nine months of 2021 (Press release, MorphoSys, NOV 2, 2021, View Source [SID1234594091]). Monjuvi is being co-commercialized by Incyte and MorphoSys in the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys will publish its full results for the first nine months and third quarter 2021 on November 10, 2021 at 10:00pm CET (4:00pm EST).
MorphoSys’ Management Board will host a conference call and webcast on November 11, 2021 at 2:00pm CET (8:00am EST) to present the first nine months and third quarter financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session.
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys’ website, www.morphosys.com.

Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.

On November 2, 2021 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, reported that its Board of Directors declared a quarterly dividend of $0.24 per share, payable on December 21, 2021 to shareholders of record on December 3, 2021 (Press release, Perrigo Company, NOV 2, 2021, View Source [SID1234594090]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 2, 2021 PierianDx, the global leader in clinical genomics knowledge, reported that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to certain conditions (Press release, PierianDx, NOV 2, 2021, View Source [SID1234594089]). The financing was led by healthcare investment firm OrbiMed with existing investors Health Catalyst Capital, Research Triangle Institute, Inova Health Systems, ATW Partners, and SJF Ventures also participating. The new capital will drive commercial expansion in response to increased demand as more healthcare organizations seek to provide high quality, affordable, faster care locally to their patients by internalizing next generation sequencing (NGS) testing capabilities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PierianDx partners directly with providers, laboratories, and medical centers of all sizes to build advanced NGS testing capabilities on site using its assay-agnostic, advanced interpretation technology and enabling services. Founded in 2014 as a technology transfer spinout from Washington University in St. Louis, PierianDx has established partnerships with industry leaders and medical facilities around the world as they build or expand upon their advanced precision medicine programs using NGS technology.

"To manifest the full impact of genomics, we must routinely apply it in clinical settings," states Rakesh Nagarajan, Founder, President, and Chief Technical and Visionary Officer of PierianDx." Our interpretation technology and services lead the way by empowering medical facilities to understand a patient’s genetic variation, identify the best treatment options, and deliver the most precise care."

"We are thrilled to work with OrbiMed and our existing investors as they share our vision for decentralized NGS testing that enables our laboratory and physician customers to better serve patients," states Mark McDonough, CEO of PierianDx. "This capital will allow us to continue building a world-class team and deliver transformative solutions to leading healthcare organizations everywhere so that they can bring genomics into their communities."